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SUMMARY
Background: Tumors arising in the colorectal area have worldwide distribution and concern mostly older popu-
lation being attributed to genetic, dietary and hormonal factors but most recently also to infection with
Helicobacter pylori (HP). Both, HP discovery and molecular biology of colorectal cancer have been recently
considered as two of ten greatest advances of gastroenterology at the dawn of 3rd millenium but little informa-
tion is available regarding the relationship between the HP and colorectal cancer. Since HP infection is usually
accompanied by an increase in plasma level of gastrin, which is also recognized as a trophic hormone for the
colonic epithelium and a potent mitogen capable to induce cyclooxygenase-2 (COX-2), we decided 1) to com-
pare the seroprevalence of HP, its cytotoxic protein, CagA, and cytokines (TNFα, IL-1β and IL-8) in colorectal
cancer patients, before and after removal of cancer, with those in age- and gender-matched controls; 2) to
determine the gene expression of gastrin and gastrin receptors (CCKB-R) in colorectal cancer tissue, 3) to assess
the plasma levels and tumor tissue contents of gastrin, 4) to examine the mRNA expression of cyclooxygenase
COX-1 and COX-2 cancer tissue and intact colonic mucosa.
Material and Methods: The trial material included 80 patients with colorectal cancers and 160 age- and gender-
matched controls. Anti-HP IgG, anti-CagA IgG seroprevalence and cytokine levels were estimated by ELISA
tests. Gene expressions of gastrin, CCKB-R, COX-1, COX-2 and Bax and Bcl2 was examined using RT-PCR,
while gastrin was measured by RIA.
Results: The HP IgG seroprevalence, especially that expressing CagA, was significantly higher in colorectal cancer
patients than in controls and did not change one week after tumor resection while plasma cytokines were signifi-
cantly reduced after this operation. Gastrin and CCKB-R mRNA were detected in the cancer tissue and the resec-
tion margin and similarly COX-2 mRNA was expressed in most of cancers and their resection margin but not in
intact colonic mucosa where only COX-1 was detected. The colorectal cancer tissue contained several folds more
immunoreactive gastrin than cancer resection margin and many folds more than the intact colonic mucosa.
Conclusions: 1) Colorectal carcinoma and its resection margin overexpress gastrin and receptors for gastrin (CCKB-
R), and COX-2; 2) here, we propose that an increased plasma level of gastrin should be considered as suitable bio-
marker of colorectal cancer, 3) HP infection may contribute to colonic cancerogenesis by enhancing expression of
gastrin and COX-2, they may account for stimulation of the tumor growth, angiogenesis and reduction in apoptosis
as evidenced an increased ratio of mRNA expression for anti-apoptotic Bcl2 over proapoptotic Bax proteins and 4)
HP positive patients who develop colorectal cancer should be subjected to the HP eradication; this is expected to
reduce hypergastrinemia and to attenuate COX-2 expression. Our final conclusion would be: treatment of patients
with colorectal cancer with COX-2 selective inhibitors now gained a strong support as a preventive measure.
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Numerous epidemiological studies demonstrated
that malignant tumors in the colorectal area are the
most common visceral malignancies concerning
mainly old adults with the highest death rates in
United States, Australia and Europe including
Poland [1,2]. In Poland, over 100, 000 new malig-
nancies are diagnosed with an yearly increase by
2–3% and with colorectal tumors representing
about 6–7% of all malignant tumors (2) (Fig. 1).
Statistical evidence established a positive relation-
ship between the occurrence of colorectal carcino-
ma (CC) and dietary factors, especially excessive
energy intake, low content of unabsorbable vege-
table fibers, intake of red meat, decreased intake
of protective microelements and a close associa-
tion of this cancer with colonic adenomas [3,4].
Besides geography and diet, an age, a family histo-
ry of CC disease, the presence of chronic colitis
and adenoma in distal colon and rectum increase
the risk of CC.
The sequence of pathological change from nor-
mal mucosa to cancer is schematically presented
at Fig. 2. As in other cancers, various genetic
alterations have been detected by the time the
colorectal tumor becomes clinically apparent
including the loss of methyl groups in DNA
(hypomethylation), occurrence of activated onco-
genes such as K-ras, allelic loss on 18q21, termed
DCC (deleted in colon cancer), mutation and
inactivation of p53 gene playing the critical role
in colon cancerogenesis [5]. Furthermore, an
overexpression of COX-2 was reported in col-
orectal cancer by numerous investigators sugges-
ting that this enzyme could be responsible for
abundant release of prostaglandins (PG), angio-
genesis and reduction in apoptosis [6–15] similar-
ly as in gastric cancer [16,17] (Fig. 3).
It is well known that the colon embryologically
arises from the same endoderm cells that form
the lining of the stomach and possesses similar
neuro-endocrine and paracrine cells releasing
various hormonal peptides and their receptors
including gastrin, that has potent mucosal growth
promoting effect on colon in animals [18] and
humans [19].
Helicobacter pylori (HP) is known to be accompa-
nied by excessive and prolonged release of gastrin
that has been suggested to account for the develop-
ment of gastric cancer [20–22] and that has been
shown to coexpress with COX-2 [22]. Since HP
infection was found to be accompanied by an over-
expression of immunoreactive gastrin that has pro-
liferative influence on colonic mucosa [18,19] we
decided to assess the relationship between HP
infection and related gastrin release and COX-2
expression in colorectal cancerogenesis. Further-
more, CC cells have been shown to express gastrin
[23], therefore, the determination of gastrin in plas-
ma and CC tissue was projected to be determined
in our CC patients. As gastrin is a potent mitogen
(23) that could induced upregulation of COX-2 and
increase the release of PG that in turn might stimu-
late angiogenesis and tumor growth [8–15], it was
rationale to determine the expression of both gas-
trin and COX-2 in the colorectal carcinoma.
The aims of this study were following; 1) to com-
pare the seroprevalence of HP and its cytotoxic
protein, CagA, in colorectal cancer patients with
that in age- and gender-matched healthy controls;
Figure 1. Colorectal cancer is more common in industrialized
‘Western’ countries, including Poland, with diets that are
high in meat, animal fat and total calories but poor in unab-
sorbable vegetable fibers.
Figure 2. Schematic presentation of the sequence of pathological
changes from normal mucosa, through adenoma, ‘carcinoma
in situ’ or severe dysplasia to colorectal cancer though the
latter rarely may arise de novo without preceding adenoma
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2) to determine the gene expression of gastrin and
gastrin receptors (CCKB-R) in colorectal cancer, its
resection margin and, for comparison, in antral
mucosa; 3) to assess the gastrin content in the plas-
ma of cancer patients and controls as well as in the
colorectal tissue, its resection margin and intact
colonic mucosa and 4) to examine the mRNA
expression of COX-1 and COX-2 as well as the
proapoptotic Bax and antiapoptotic Bcl2 protein
expression in the colorectal cancer and its resec-
tion margin.
We found that the colorectal cancer and its resec-
tion margin contains higher amounts of gastrin than
the intact colonic mucosa and that cancer and its
resection margin are capable of expressing mRNA
for gastrin and gastrin-receptors (CCKB-R), for COX-
1 and COX-2 and for anti-apoptotic Bcl2 rather
than proapoptotic Bax and to release large
amounts of immunoreactive gastrin that could
locally stimulate (by autocrine or paracrine path-
way) the tumor cell proliferation and possibly also
to induce COX-2 expression in the cancer and sur-
rounding mucosa.
MATERIAL AND METHODS
The studies were carried out on 40 histologically
verified colorectal carcinoma (35 men and 5
women) with the median age of 64 years (range 47
to 82 years) and 160 controls (130 men, 30
women) with the median age of 63 years (range
from 47 to 82 years). Patients symptoms, age, gen-
der, tumor site and its histology were recorded at
Figure 3. Major steps in cascade of colorectal cancerogensis
Figure 4. Examples of colorectal cancers of ascending colon and sigmoid macroscopical and microscopical or radiological examinations.
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the Department of General Surgery of District Hos-
pital of Cracow, Department of Gastroenterology
of Pomeranian Medical University, Szczecin and
Department of Medicine, University of Erlangen-
Nuremberg, Erlangen, Germany and Department
of Physiology, Jagiellonian University School of
Medicine, Cracow, Poland. Before the surgery, gas-
troscopy was performed to obtain mucosal biopsy
from the gastric corpus and the antrum for histo-
logy and for comparison of the mRNA expression
of gastrin and its receptors (CCKB-R) with those in
colorectal cancers. During the surgery, the large
biopsy samples were taken from the tumor, the
resection margin and intact colonic mucosa at the
remote site from the cancer for routine histological
examination to determine the stage and histologi-
cal type of the tumor and for gene expression of
gastrin and its CCKB-R, COX-1 and COX-2 and Bax
and Bcl2. The tumors were identified histologically
as colorectal tubular (70%) and tubulovillous carci-
noma (30%) [5]. Examples of macroscopic, endo-
scopic, CT and microscopic pictures of colorectal
cancers are presented on Figs 4 and 5.
The HP infection status was assessed by our modi-
fication of capsulated minidose 13C-Urea Breath
Test (UBT) as described earlier [24] and/or by
determination of IgG antibodies to HP by enzyme
linked immunosorbent assay (ELISA) using com-
mercially available kit (EIAGEN HP IgG, Clone
Systems, Italy). Titers higher than 15 AU/ml were
considered positive (following the manufacturer
recommendations). IgG antibodies against CagA
were detected by ELISA using recombinant CagA
kindly provided Ora Vax Cambridge, USA as pre-
viously [21,22,24].
For the determination of the mRNA expression of
gastrin, CCKB-R, COX-1 and COX-2 and Bax and
Bcl2 the analysis of reverse transcription-poly-
merase chain reaction (RT-PCR) was applied and
the tissue content of gastrin was measured using
Figure 5. Examples of colorectal cancer of ascending sigmoid macroscopically and in CT (on left) and of caecum at endoscopy and radiology (on
right)
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RIA. For this purpose larger tumor (~100 mg),
tumor resection margin (~100 mg) and intact
colonic mucosa samples were taken and frozen
immediately in the liquid nitrogen for the detec-
tion of the signals for gastrin and gastrin receptors
as well as COX-1 and COX-2 and Bax and Bcl2 by
reverse transcriptase-polymerase chain reaction
(RT-PCR) as described earlier [22,25,26]. Tumor,
resection margin and intact mucosa samples were
also homogenized in phosphate buffer at pH 7.7
and 0°C for 10 s with Ultra-Turrax T-25, Ika
Labortechnik, Staufen, Germany. The homoge-
nized samples were processed as for plasma gastrin
RIA using gastrin antiserum, 4562 (kindly donated
by Professor J.E. Rehfeld of Copenhagen,
Denmark) in the final dilution of 1:500 000. The
antibody 4562 recognize amidated G-13, G-17
and G-34 equally. The sensitivity of the present
assay was 2.5 pmol/mL plasma equivalent to hu-
man G-17. Blood samples were collected preope-
ratively and in some patients also one week after
the surgery from peripheral vein under basal con-
ditions and after separation of the plasma they
were stored at -70°C for gastrin RIA as described
before [21,27].
RT-PCR and detection of amplified gene products
were performed using the above mentioned large
biopsy specimens obtained during surgery. For this
purpose, total cellular RNA was isolated from these
specimens using TRIzol Reagent (Gibco BRL, UK).
Briefly, tissue samples placed in to the liquid nitro-
gen and then transferred to TRIzol Reagent and
homogenized. After addition of chloroform the
aqueous phase was separated by 13000 rpm spin
in 4°C for 10 min. RNA was precipitated using iso-
propyl alcohol, washed with 75% ethanol and
resuspended in DEPC treated water. 1 mg of total
cellular RNA was used for the synthesis of cDNA in
RT-PCR reaction (Promega Reverse Transcription
System). The final concentration of components in
20 ml of total reaction volume was as follows;
5 mM MgCl2, 1x Reverse Transcription Buffer
(10 mM Tries-HCl, 50 mM KCl, 0.1% Triton X-100),
1 ml each dNTP 1 U/ml Recombinant RNasin
Ribonuclease Inhibitor, 15 U/mg AMV Reverse
Transcriptase 0.5mg Oligo(dT)15 Primer per micro-
gram RNA. Samples were incubated at 42°C for 15
minutes and heated at 99°C for 5 minutes followed
by a 5 min incubation at 0–4°C.
The PCR reactions were prepared in 1 x
Dynazyme PCR buffer (Flowgen) with 40 mmol
dNTPs (Pharmacia) and 10 mmol of upper and
lower primers. The following primer pairs for PCR
reaction were used: 5’-GCC CAG CCT CTC ATC
ATC as a sense primer 3’-GGG GAC AGG GCT
GAA GTG - antisense for gastrin; 5’-TCT CGC GAG
CTC TAC TTA GGG as sense primer and 3’-GAA
GTT GCA CGT AGC AGC CA - antisense for CCKB-
R; 5’-AGC GGG AAA TCG TGC GTG as sense
primer and 3’-GGG TAC ATG GTG GTG CCG as
antisense for β-actin; 5’-GCA ACA CTG GAA CAT
GGC TA-3’ as a sense primer and 5’ACG CCA
CCA TTC TGT CTT TG-3’ as an antisense primer
for COX-1; and 5’-TCA TTC ACC AGG CAA ATT
GCT GGC AGG G-3’ as a sense primer and 5’-ACA
GTT CAG TCG AAC GTT CTT TTA GTA GTAC-3’
as an antisense primer for COX-2, 5’ TGG CAG
CTG ACA TGF TTT CTG AC as sense primer and 3’
CGT CCC AAC CAG GGT CT as antisense for Bax,
5’ CAG ATG CAC CTG ACG CCC TT as sense
primer and 3’ CCC AGC CTG CGT TAT CCT GGA
as antisense for Bcl2, as described before [26].
The thermal profile for all these reactions was the
same; 95°C for 5 min before 40 cycles or 95°C for
45 s, 60°C for 90 s, and 72°C for 90 s. This was fol-
lowed by a single stage of 60°C for 120 s and 72°C
for 180 s. PCR products were analyzed by agarose
gel electrophoresis and abundance of cDNA in
each sample was estimated by video densitometry
analysis (Fotodyne, USA) using Gel-Pro Analyzer
program and expressed as a ratio versus calculated
intensity of β-actin product used as a reference
gene. In the case of the gastrin gene products the
intensity of two bands (215 bp and 345bp) were
summrized and the same procedure was applied
to express the results.
Statistical analysis
The analyzed groups were those with HP-, CagA-
seropositivity and plasma levels and tissue
immunoreactive gastrin contents in patients with
gastric cancer and controls. In general, rank sum
test, Sperman’s rank test order correlation was
used for relation between independent variables. A
P value of less than 0.05 was accepted as signifi-
cant.
RESULTS
The prevalence of HP seropositivity reached ~85%
in colorectal cancer patients but only 60% in con-
trols and this difference in HP seropositivity
between cancers and controls was statistically sig-
nificant. The CagA seropositivity in colorectal can-
cer patients was about twice as high (42%) as in
controls (20%) and this difference was also statisti-
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cally significant. The UBT in cancer patients was
positive only in 65%, while in controls it was posi-
tive in 57% of tested cases.
Basal plasma levels of TNFα, IL-1β and IL-8
showed significant decrease one week after the
removal of colorectal cancer but the HP and CagA
seropositivity remained the same as before the
surgery and these results are not included.
Basal plasma amidated gastrin levels in colorectal
cancer patients were about 53±12 pM and they
were about over twice as high as those in controls
(21±5 pM). One week after removal of colorectal
cancer, the plasma gastrin level was reduced by
about 20% significantly altered (40±6 pM before
surgery vs 25±3 pM after surgery). The gastrin con-
tents in colorectal cancer tissue were about 6.5
and 5 pmol/g of wet tissue weight and it was about
three times higher than at the resection margin and
20 times more than in the macroscopically normal
antral mucosa. This difference between the plasma
gastrin concentration in cancer patients and in
healthy controls as well as between the gastrin con-
tent in tumor tissue, resection margin and intact
colonic mucosa was highly statistically significant.
Fig. 6 shows the diagram illustrating the posttrans-
lational processing of pre-progastrin into progastrin
Figure 6. The post-translational processing of pre-progastrin into progastrin and amidated gastrins (G-13, G-17, G-34) in G-cells located mainly in
antrum and duodenum and into progastrin in colorectal cancer (on right) 
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in colorectal cancer cells and in amidated gastrins
(G-13, G-17 and G-34) in G-cells in antro-duode-
nal area and in gastric cancer cells.
The tumor tissue of all cancer patients showed
mRNA expression for gastrin, though this expression
was relatively small in 3 out of 12 examined cancers,
and similar expression was detected in antral biopsy
samples taken from these patients. The ratio of gas-
trin mRNA to β-actin mRNA varied from case to case
and it was in 8 of 12 examined cases somewhat
higher in the cancer tissue than in resection margin
and similar to that in the intact antral mucosa. The
mRNA expression for gastrin receptor (CCKB-R) signal
was observed in all except one tumor and in 8 of 12
resection margins of these tumors and in case of can-
cer tissue it was similar to that in intact mucosa of
gastric corpus. The ratio of CCKB-R mRNA to β-actin
mRNA was higher in the majority of cases in tumor
tissue than in resection margin and reached the va-
lues similar to that in intact mucosa of gastric corpus
of these patients. This ratio was negligible in the
antrum mucosa and these results have been omitted
for the sake of clarity.
The COX-1 mRNA was expressed in the cancer tis-
sue and the resection margin as well as in intact
colonic mucosa. COX-2 mRNA expression was
pronounced in all, except one, of the cancer tissue
samples and in 9 of 12 of the resection margins but
was not detectable in the intact colonic mucosa. In
8 of 12 cases tested, the COX-2 mRNA expression
was higher in the tumor tissue than in resection
margin (Fig. 7).
Bax and Bcl2 mRNA were expressed both in tumor
tissue and the resection margin. The Bcl2 expres-
sion was stronger than that of Bax in the cancer tis-
sue and the ratio of Bax to Bcl2 was smaller in 10
of 12 tumors than at their resection margins.
Therefore, the major difference in apoptosis-rela-
ted gene expression between the cancer tissue and
resection margin was enhanced level of mRNA for
Bcl2 rather than for Bax in cancer tissue when com-
pared to resection margin.
DISCUSSION
This study confirms previous observations that
colon tumors including low grade MALT lym-
phoma are strongly associated with CagA-positive
HP infection [25,28–30] and shows that this infec-
tion in cancer patients is accompanied by an
increased mRNA expression for gastrin and its
receptors, for COX-2 and for anti-apoptotic Bcl2 in
the tumor tissues.
The reason for the higher HP seroprevalence in the
colorectal cancer patients is not known but this
infection results in a significant increase in plasma
gastrin level possibly due to the impairment by HP
of the local control of the G-cell activity by somato-
statin in gastric antrum [31] or to direct stimulatory
influence of the HP-originating histamine metabo-
lite (Nαmethyl histamine), a potent luminally ac-
ting gastrin releaser [32,33]. It is of interest that
increased rate of HP infection in colorectal cancer
was estimated mainly from the positive serology
anti-HP IgG, while UBT was positive in relatively
smaller percentage of these patients (as compared
to controls) probably because of the gastric muco-
sal atrophic changes that may interfere with the
UBT as reported previously [21,34,35].
The question remains whether this higher HP sero-
prevalence plays any role in the pathogenesis of
colorectal cancer but the fact that this infection is
accompanied by an increased plasma level of gas-
trin reported previously [30,31,34] and observed
also in this study, suggests that this hormone could
contribute to the colorectal cancerogenesis by
inducing higher mucosal cell proliferation of colon
[19]. As described by Kinzler and Vogelstein [36]
the colon cancer development starts with hyper-
plasia/dysplasia, progressing through adenoma to
carcinoma (see Fig. 2). This finally leads to induc-
tion of COX-2 as it happens in other cancers
[34–39]. Previous studies showed that gastrin gene
is expressed by colorectal cell lines and by primary
colon cancer [40–44] suggesting an autocrine role
Figure 7. Expression of COX-2 and actin and ratio of COX-2 to actin in
colorectal cancer and its margin 
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of gastrin in the growth of colon cancer cells but
plasma levels were either not measured in those
studies [25–28].
The main finding of the present study is the observa-
tion that the colorectal cancer tissue and resection
margin express mRNA for gastrin and CCKB-R and
contain several fold higher content of immunoreac-
tive amidated gastrin than the intact colonic
mucosa. This indicates that the greatly increased
gastrin in the plasma originated predominantly from
the colorectal cancer and that besides the antral G-
cells, the colorectal cancer tissue could contribute,
to the increased plasma levels of this hormone
though the fact that following removal of cancer
there was relatively small decrease in plasma gastrin,
was observed militates against the major involve-
ment of gastrin-producing colorectal cancer cells to
the elevated plasma hormone concentration in can-
cer patients.
Our finding that colorectal cancers exhibit higher
expression and content of gastrin and its receptors
reminds similar upregulation of gastrin biosynthesis
described previously by our group in gastric can-
cers [21,39]. The major difference between gastric
cancer and colorectal cancer is an overexpression
of gastrin that seems to be the major product of the
posttranslational changes of pre-progastrin in co-
lorectal but not in gastric cancer tissue. As gastrin is
known to be the powerful mucosal growth promo-
ting factor in gastrointestinal tract [17,18,23] it is
tempting to assume that this hormone could play a
key role in the initiation and the progression of
cancer disease both in the stomach and in the
colon, both originating embryologically from the
same endoderm tube [45]. This is supported by
recent reports that gastrin peptides and their
receptors are invariably coexpressed in the adeno-
carcinoma of the pancreas [46] or the liver [47]
that also originates from the same endoderm as the
stomach and gut. This study suggests that gastrin
produced by pancreatic cancer cells may be an
autocrine factor in carcinoma arising also from the
pancreatic acinar cells. These studies are of parti-
cular interest because they show that in addition to
amidated gastrin, glycine-extended gastrins as well
as N-terminal progastrins were detected in the
pancreatic and liver cancer and all appear to
exhibit the growth promoting effects as amidated
gastrin itself. Recently, Singh et al, [48] using trans-
genic mice overexpressing either progastrin or ami-
dated gastrin found that the risk of colonic can-
cerogenesis is significantly increased in mice
expressing progastrin rather than amidated gastrin.
It is not clear whether in colorectal cancer in
humans the increased levels of progastrin enhance
the risk for developing of adenocarcinoma in the
colon [23] but our results are in keeping with that
noition.
Epidemiological studies indicate that the use of
aspirin and other NSAID, whose major target is
cyclooxygenase, a rate limiting enzyme converting
arachidonic acid to prostanoids, decreases the inci-
dence and mortality from colorectal cancers
[11–16] (Fig. 8). COX-2 has been found to occur
frequently in the colorectal cancer where it is held
responsible for the production of excessive
amounts of PG, tumor cell proliferation, angiogen-
Figure 8. Angiogenesis is stimulated by COX-2 and its products
including prostaglandins, VEGF, TGFα, EGF, bFGF, angiopo-
etins and other angiogenic substances involved in tumor
growth and progression. This process depends upon the
induction of COX-2 probably by progastrin and other growth
factors generated in the cancer tissue. COX-2 overexpression
results in the growth of endothelial cells and formation of
new capillaries in the growing tumor
Blocking COX-2 by non-specific agents such as aspirin or by
more specific COX-2 blockers (e.g. Vioxx lub Celecoxib),
limits angiogenesis and slows down the tumor growth.
Suppression of angiogenesis or the application of agents that
diretcly reduce the amount of blood flowing to the cancer
(e.g. Neovastat, Semaxanib) results in the reduction in the
blood flow to the cancers cells which then become the tar-
gets of immunological system. (modified from L. Tweeten,
Time 2001).
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esis, reduction in apoptosis and tumor invasiveness
[15,16]. Assuming that HP and gastrin are initiators
of colorectal carcinogenesis, the excessive produc-
tion of prostanoids might be implicated in the pro-
motion of this process and could be a target for the
chemotherapy using specific COX-2 inhibitors
[14–17]. Our results confirm the gene expression
of both COX-1 and COX-2 in the colorectal cancer
and thus, supports the notion that, indeed, COX-1
and COX-2 derived prostanoids may play a role in
the development of colorectal cancer and should
be a target of treatment using specific COX-2
inhibitors. As the elimination of the initiator of co-
lorectal cancerogenesis such as increased progas-
trin and gastrin production may not be at present
possible, the inhibition of the promotion of this
process, particularly of angiogenesis and tumor
growth could be attained by application of novel
anti-inflammatory drugs. Based on our data that
the HP is commonly infecting the colorectal cancer
patients and leads to hypergastrinemia and COX-2
expression, both factors probably responsible for
the initiation and promotion of colorectal cancer, it
seems advisable to eradicate the HP in cancer
patients to prevent or to attenuate the progression
of colorectal cancer.
The growth rate of colorectal tumors, like other
neoplasia, depends upon the perturbation in the
balance between the cell division and cell death
through apoptosis [49,50].
Several families of proteins have ability to modu-
late apoptosis, perhaps the most well known of
which is the Bcl2 that appears to repress apoptosis
and Bax that promotes this process. Overexpres-
sion of Bcl2 has been reported in a wide variety of
cancers including colorectal, lung, prostate and
other solid tumors and Bcl2 has been held respon-
sible for the blockade of the programmed cell
death [51–53] and consequently for the tumor
growth and relative resistance to chemotherapeu-
tic drugs. Our study confirms previous reports
[53,54] that the mRNA expression for Bcl2 domi-
nates in colorectal cancer tissues and shows for
the first time that Bcl2 mRNA is expressed more
intensively in colorectal tumors, while Bax mRNA
is expressed to similar extent in both the tumor
and the resection margin of this tumor. As tumor
tissue was also found to produce greater amounts
of gastrin and to express more COX-2 than the
resection margin, it may be reasonably to assume
that the primary event in colorectal cancerogene-
sis is an excessive local biosynthesis of gastrin (pro-
gastrin and amidated gastrin) that in turn, as a
potent mitogen, could induce COX-2 expression
resulting in the reduction in apoptosis in the
tumor tissue (Fig. 9). This requires normal activity
of P53, which is considered as a guardian of
genome. When P53 is mutated and inactivated,
the damage of DNA is nor repaired and replica-
tion of such damaged DNA continues with tumor
growth. The decrease in apoptosis in the cancer
tissue might be responsible for the uncontrolled
cell proliferation and tumor growth. The overex-
pression of COX-2 and related overproduction of
PG and angiogenic factors that might be responsi-
ble for further stimulation of cancer growth, angio-
genesis and invasiveness could represent a poten-
tial target of chemotherapy by COX-2 specific
blockers but this requires adequate clinical trials.
CONCLUSIONS
1. Colorectal carcinoma and its resection margin
overexpress gastrin and receptors for gastrin
(CCKB-R), and COX-2. 
2. Here, we propose that an increased plasma level
of gastrin should be considered as suitable bio-
marker of colorectal cancer; 
3. HP infection may contribute to colonic cancero-
genesis by enhancing expression of gastrin and
COX-2, they may account for stimulation of the
tumor growth, angiogenesis and reduction in
apoptosis as evidenced by an increased ratio of
mRNA expression for anti-apoptotic Bcl2 over
proapoptotic Bax proteins; and 
4. HP positive patients who develop colorectal
cancer should be subjected to the HP eradica-
tion; this is expected to reduce hypergastrinemia
and to attenuate COX-2 expression. Our final
conclusion would be: treatment of patients with
Figure 9. P53 - guardian of genom
1180
Basic Research
colorectal cancer with COX-2 selective inhibitors
now gained a strong support as a preventive
measure.
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